GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Singular Genomics Systems
Singular Genomics is a company developing next-generation sequencing systems. Its stock price reflects its efforts to compete with the giant Illumina. The chart tells the story of the battle for market share, where value is determined by technological advantage, speed, and cost of genome analysis.
Share prices of companies in the market segment - Dna
Singular Genomics Systems develops and sells next-generation sequencing systems for genome analysis, designed to be faster and more flexible than competitors. We've categorized it as "DNA." The chart below shows how investors value companies in the competitive genomics equipment sector.
Broad Market Index - GURU.Markets
Singular Genomics Systems develops and markets next-generation sequencing systems for genome analysis, designed to be faster and more flexible than competitors. We've categorized it as "DNA." The chart below shows how investors value companies in the competitive genomics equipment sector.
Change in the price of a company, segment, and market as a whole per day
OMIC - Daily change in the company's share price Singular Genomics Systems
For Singular Genomics Systems Inc., a sequencing company, daily volatility reflects sensitivity to competition. This metric is an indicator of demand for its equipment from research labs.
Daily change in the price of a set of shares in a market segment - Dna
Singular Genomics Systems develops and markets next-generation sequencers for genetic analysis. The genomics equipment market is highly technological and competitive. The graph below shows the average volatility in this sector, allowing one to assess how the market is adopting OMIC's innovations.
Daily change in the price of a broad market stock, index - GURU.Markets
Singular Genomics develops and sells next-generation genome sequencing machines. This science-intensive company's shares are a bet on the future of genetics. Their high, speculative volatility is part of the dynamics of the innovation sector, which influences the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Singular Genomics Systems
Singular Genomics Systems' year-over-year performance tells the story of its battle for DNA sequencing market share. Its market cap change over the past 12 months reflects its success in commercializing its G4 desktop sequencer. Its valuation is a bet on its ability to compete with giant Illumina by offering speed and flexibility.
Annual dynamics of market capitalization of the market segment - Dna
Singular, as a company developing DNA sequencing systems, is betting on the future of genomics. Its performance relative to the sector will determine how well its technology competes with the dominant Illumina and how it is impacted by R&D budgets in the life sciences.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Singular Genomics, a manufacturer of next-generation sequencers, competes with Illumina in the genetic analysis market. Its year-over-year market capitalization reflects the success of its technology in penetrating research labs.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Singular Genomics Systems
Singular is a biotech company that produces genome sequencing systems. Its monthly performance reflects the pace of adoption of its G4 platform in research labs and growing sales of consumables, which are key to its business model.
Monthly dynamics of market capitalization of the market segment - Dna
Singular Genomics Systems develops and markets next-generation sequencers for genome analysis. Their goal is to make genomic research faster, more flexible, and more accessible. The graph below illustrates the overall dynamics of the DNA technology sector, where there is a constant race to reduce the cost and speed up genome reading.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of genomic research equipment makers are betting on the "shovels and picks" of the biotech revolution. The chart below shows the overall risk appetite. Is Singular Genomics Systems moving in sync with the growth market, or is its performance driven by competition in its niche?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Singular Genomics Systems
Shares of Singular Genomics, a DNA sequencing company, reflect competition in the genomics technology market on a weekly basis. Price movements reflect the performance of its instruments and the company's ability to compete with the giant Illumina.
Weekly dynamics of market capitalization of the market segment - Dna
Singular Genomics Systems is developing a new generation of DNA sequencers. This is a high-tech and competitive market. The chart will allow us to compare its weekly performance with the sector and understand how its G4 technology competes with giants like Illumina and influences its valuation.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Singular Genomics is a biotech company whose value depends on the deployment of its technologies. Shares in this sector often move independently of the market. This chart will help you understand: do Singular shares follow the broader market, or do news about its developments create a completely independent trajectory?
Market capitalization of the company, segment and market as a whole
OMIC - Market capitalization of the company Singular Genomics Systems
Singular Genomics' market capitalization chart tells the story of a company attempting to challenge giant Illumina in the genome sequencing market. Its post-IPO decline highlights the immense difficulty of competing with an established leader. Its performance reflects the market's assessment of its technology and its chances of capturing even a small share of this strategically important market.
OMIC - Share of the company's market capitalization Singular Genomics Systems within the market segment - Dna
Singular Genomics develops next-generation sequencers for genetic analysis. Its market capitalization reflects its technological ambitions and competition with market leader Illumina. The chart shows how investors assess its chances of capturing a share of this promising market.
Market capitalization of the market segment - Dna
Singular Genomics is a manufacturer of next-generation sequencers for genetic analysis. The chart below shows the market capitalization of the life sciences sector. Its dynamics reflect the technological race to reduce the cost and speed of DNA reading, in which Singular is attempting to compete with the giant Illumina.
Market capitalization of all companies included in a broad market index - GURU.Markets
Singular Genomics Systems produces next-generation DNA sequencers. Its market cap reflects the fact that its technology will make genetic analysis faster and cheaper. Its performance on the overall chart reflects the technological race in the world of genomics, which is driving the entire field of biomedical science forward.
Book value capitalization of the company, segment and market as a whole
OMIC - Book value capitalization of the company Singular Genomics Systems
Singular Genomics' book value is its capital and production capacity for next-generation benchtop sequencers. This is real, science-intensive capital aimed at making genomic analysis faster and more accessible. How has this technological asset changed in the face of competition? The chart below shows its dynamics.
OMIC - Share of the company's book capitalization Singular Genomics Systems within the market segment - Dna
Singular Genomics produces next-generation sequencing equipment (G4 sequencers). The chart shows the proportion of its R&D and manufacturing assets, reflecting the physical scale behind the creation of genomic research tools.
Market segment balance sheet capitalization - Dna
Singular Genomics, a sequencing machine manufacturer, is a capital-intensive business. It requires cleanroom facilities to build its complex machines. The BCap_Seg chart for the medical equipment sector shows that success in this sector requires a substantial manufacturing base.
Book value of all companies included in the broad market index - GURU.Markets
Singular Genomics' assets are its technology and the G4 desktop DNA sequencers it produces. Its book value reflects its patents and manufacturing capabilities for creating these complex scientific instruments. The chart provides an estimate of the material weight of this new player in the genomics market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Singular Genomics Systems
Singular Genomics creates genome sequencing equipment. Its balance sheet consists of manufactured devices and patents. Its market valuation is a bet that its technology will be faster and cheaper than its competitors. The graph shows the premium the market is willing to pay for technological superiority in the "genome race."
Market to book capitalization ratio in a market segment - Dna
Singular Genomics Systems develops and markets next-generation sequencers for gene analysis. It's a high-tech company, and its market valuation on the chart reflects the potential of its equipment in the rapidly growing and competitive genomic research market.
Market to book capitalization ratio for the market as a whole
Singular Genomics Systems creates genetic sequencing equipment, combining high technology and manufacturing. The market values both its technological superiority and the company's ability to scale production. This chart compares the company's valuation of this high-tech company with overall market trends.
Debts of the company, segment and market as a whole
OMIC - Company debts Singular Genomics Systems
Singular Genomics, a company developing next-generation sequencers, uses capital for R&D and commercialization of its technology. This chart shows how the company is funding its battle for market share in genomic sequencing, aiming to offer scientists faster and cheaper research tools.
Market segment debts - Dna
Singular Genomics Systems develops and markets next-generation DNA sequencers. The genomics equipment market is capital-intensive and requires constant innovation. This chart shows how the young company funds its R&D and production to compete with a giant like Illumina, and how much it relies on outside capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Singular Genomics Systems
Singular Genomics Systems develops and sells next-generation gene sequencing equipment. This is a high-tech and competitive market. This chart shows how the company uses debt to finance its R&D, production, and competition with industry giants. It helps assess its financial strategy and risks.
Market segment debt to market segment book capitalization - Dna
Singular Genomics Systems develops and sells next-generation DNA sequencing equipment. This market is highly competitive, dominated by the giant Illumina. The chart shows how the biotech sector uses debt for R&D, providing context for how Singular finances its battle for market share.
Debt to book value of all companies in the market
Singular Genomics Systems is developing next-generation sequencers, which requires significant investment in R&D and high-tech manufacturing. This chart, showing the overall market debt burden, helps assess how the company, in the competitive biotech equipment field, is financing its innovations and the sustainability of its debt strategy.
P/E of the company, segment and market as a whole
P/E - Singular Genomics Systems
Singular Genomics Systems develops and sells next-generation sequencers for genetic analysis. This chart shows how the market is evaluating its sequencing technology. The dynamics reflect competition with industry giants and the company's ability to offer faster and cheaper solutions for scientific research.
P/E of the market segment - Dna
This industry chart for biotech tool companies is a benchmark for Singular Genomics. It shows the high valuations investors place on this sector. Comparisons with it help understand how the market values Singular's genome sequencing technology and whether it believes it can compete with the giant Illumina.
P/E of the market as a whole
Singular Genomics is a company developing DNA sequencing technologies. Its valuation is a bet on its ability to compete with giants like Illumina. It's not tied to the general economic cycles reflected in this chart, but depends on its technological breakthroughs and research budgets.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Singular Genomics Systems
This chart from Singular Genomics Systems, a company that produces next-generation sequencers, shows market expectations for future sales of its equipment. It reflects analysts' confidence in the company's ability to compete with market leaders thanks to the speed and flexibility of its systems.
%20P%2FE%20Singular%20Genomics%20Systems&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Singular-Genomics-Systems&v=1772584118449 "Chart of the company's future (projected) P/E Singular Genomics Systems")
Future (projected) P/E of the market segment - Dna
Singular Genomics Systems develops and markets next-generation sequencers for gene analysis. The company's goal is to provide researchers with faster, more flexible, and more accurate tools. The chart shows forecasts for the life sciences sector. This helps assess how the market perceives Singular's ability to compete with giant Illumina in the DNA sequencing market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772584118540 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Singular Genomics Systems Inc. develops and markets next-generation sequencing systems for genome analysis. The company operates in a rapidly growing but highly competitive market. This graph of expectations for the tech and biotech sectors shows how much investors believe in the ability of new players to disrupt market leaders.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772584118585 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Singular Genomics Systems
Singular Genomics Systems produces next-generation DNA sequencers. The company's profits depend on sales of these complex and expensive instruments to research labs and clinics. This chart shows how the company competes with the giant Illumina in the rapidly growing genomics technology market, where innovation is costly.
Profit of companies in the market segment - Dna
Singular Genomics Systems develops and markets next-generation DNA sequencers. This sector profitability chart demonstrates how rapidly genomics is advancing. Their G4 technology is designed to make sequencing faster, more flexible, and more accessible, accelerating scientific discoveries and the integration of genetic analysis into clinical practice.
Overall market profit
Singular Genomics Systems develops and sells next-generation sequencers for genome analysis. The company strives to make genetic analysis faster and cheaper. Demand for its equipment depends on the volume of research in biology and medicine. Economic growth, reflected in this graph, stimulates investment in science, which is a driver for such companies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Singular Genomics Systems
Singular Genomics Systems develops and markets next-generation sequencers for genome analysis. The company strives to offer faster and more flexible solutions for researchers. This chart shows how analysts assess the company's ability to compete with market giants and grow sales of its equipment and consumables.
%20profit%20of%20the%20company%20Singular%20Genomics%20Systems&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Singular-Genomics-Systems&v=1772584118692 "Graph of future (projected) profit of the company Singular Genomics Systems")
Future (predicted) profit of companies in the market segment - Dna
Singular Genomics Systems develops and markets next-generation sequencers for analyzing genomes and other biological molecules. The company strives to offer faster and more flexible solutions for researchers. Growth depends on competition in the genomics equipment market. This biotech chart reflects expected growth in the genetic research market, which is the foundation of Singular's business.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772584118702 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Singular Genomics Systems produces next-generation sequencers for genetic analysis. Demand for its equipment depends on the budgets of scientific laboratories and biotech companies. This graph, reflecting revenue forecasts, influences funding allocated to research and development (R&D).
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772584118750 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Singular Genomics Systems
Singular Genomics Systems develops and markets next-generation sequencers for genetic analysis. The chart shows a high valuation for each dollar of its revenue. This reflects investors' belief that its technology can compete with market leaders, offering greater speed and flexibility, which is crucial for scientific research.
P/S market segment - Dna
Singular Genomics Systems develops and sells next-generation sequencers for genome analysis. The company's revenue depends on sales of these devices and their consumables. This chart, which reflects the average valuation in the sector, helps understand how investors view Singular's technology and competitive position in the rapidly growing and competitive world of genomics.
P/S of the market as a whole
Singular Genomics Systems develops and markets next-generation sequencing systems for genome analysis, which promise to be faster and more flexible than existing systems. This chart, showing average market revenue estimates, helps us understand the premium investors are willing to pay for technologies that are the "pix and shovel" of the genomics and personalized medicine revolution.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Singular Genomics Systems
Singular Genomics Systems develops and markets next-generation sequencing systems for genome analysis. Its goal is to make genetic analysis faster and more accessible. This chart shows how investors assess the company's ability to compete with market giants like Illumina and capture market share in the rapidly growing genomics market.
%20P%2FS%20Singular%20Genomics%20Systems&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Singular-Genomics-Systems&v=1772584118929 "The graph of the company's future (projected) P/S Singular Genomics Systems")
Future (projected) P/S of the market segment - Dna
Singular Genomics Systems, Inc. develops and commercializes next-generation sequencing systems and multi-omics technologies for use in scientific research and clinical diagnostics. This chart shows the average estimated future sales in the life sciences sector. It helps understand how the market views Singular Genomics' competitive position in the rapidly growing field of genomics.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772584119072 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Singular Genomics Systems develops and markets next-generation sequencers for analyzing genomes and other biological molecules. This chart shows the market's collective revenue expectations. The company's technologies are designed to make genetic analysis faster and less expensive, accelerating scientific research and the implementation of genomics in clinical practice.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772584119112 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Singular Genomics Systems
This chart shows sales of Singular Genomics Systems, a company that manufactures and sells benchtop next-generation DNA sequencing systems. Revenue is generated from sales of these systems and the consumables required for their operation. The trend reflects the demand for genomic technologies in scientific research.
Sales of companies in the market segment - Dna
Singular Genomics Systems develops and manufactures next-generation DNA sequencers designed for high-throughput and accurate genome analysis. This graph illustrates the growth of the biotechnology equipment market. The company's technologies are designed to make genetic analysis faster and more accessible, a key factor in advances in oncology and genetics.
Overall market sales
Singular Genomics Systems produces next-generation sequencers for genetic analysis. Demand for its equipment comes from research labs and clinics. This total revenue chart reflects the state of the economy, which impacts budgets for scientific research and the implementation of new technologies in medicine.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Singular Genomics Systems
Singular Genomics develops and markets high-throughput next-generation DNA sequencing systems. The company's future revenue depends on sales of its equipment to research laboratories and clinics. The chart shows analyst expectations for the competitive genomics technology market.
%20sales%20of%20the%20company%20Singular%20Genomics%20Systems&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Singular-Genomics-Systems&v=1772584119378 "Schedule of future (projected) sales of the company Singular Genomics Systems")
Future (projected) sales of companies in the market segment - Dna
Singular Genomics Systems develops and markets next-generation sequencers for genome analysis. The company strives to offer scientists faster, more flexible, and more powerful tools for genetic research. This chart shows the forecast for the entire DNA technology market, where Singular Genomics competes for a share of this rapidly growing segment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772584119446 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Singular Genomics Systems develops and markets next-generation sequencers for genome analysis. Demand for their equipment depends on funding for biomedical research. This dynamic, reflecting the overall economic situation, influences public and private research budgets, which are the primary source of demand for Singular's products.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772584119588 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Singular Genomics Systems
Singular Genomics Systems develops and sells next-generation sequencers for genome analysis. The company's profitability depends on sales of this sophisticated equipment and its consumables. This chart shows how the company competes in the high-tech genetic analysis market, striving to offer scientists faster and more accurate tools.
Market segment marginality - Dna
Singular Genomics Systems develops and markets high-throughput next-generation sequencing (NGS) systems. Early commercialization profitability depends on successful sales of their sophisticated instruments and associated consumables. This chart reflects the financial costs of market entry and competition in the rapidly growing genomics sector.
Market marginality as a whole
Singular Genomics Systems develops and markets next-generation sequencers for genome analysis. Their goal is to make genetic analysis faster, more flexible, and more accurate. This overall profitability curve is important to them because it impacts the budgets of their clients—research institutes and biotech companies that invest in new equipment during periods of growth.
Employees in the company, segment and market as a whole
Number of employees in the company Singular Genomics Systems
Singular Genomics develops and markets next-generation DNA sequencing systems. Its team consists of engineers and scientists committed to competing with industry giants. This chart reflects its investment in R&D and efforts to build manufacturing and commercial capabilities.
Share of the company's employees Singular Genomics Systems within the market segment - Dna
Singular Genomics Systems develops and markets next-generation sequencers for genetic research. This chart reflects the company's engineering and manufacturing scale. It shows the proportion of specialists in this competitive industry dedicated to creating and promoting innovative equipment that makes genetic analysis faster and more accessible.
Number of employees in the market segment - Dna
Singular Genomics Systems, Inc. is a company developing and commercializing next-generation DNA sequencers. This chart illustrates employment trends in the biotechnology equipment sector. The growing number of engineers and bioinformaticians reflects the race to create faster and cheaper genome reading technologies, which are key to revolutionizing personalized medicine.
Number of employees in the market as a whole
Singular Genomics Systems produces next-generation sequencers for genetic research. Demand for its equipment depends on the budgets of scientific and medical institutions. The overall economic growth, visible in this graph, is driving increased public and private funding in genomics, which is a driver for the company.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Singular Genomics Systems (OMIC)
Singular Genomics Systems produces equipment (sequencers) and reagents for genetic analysis. In the life science tools sector, this chart reflects the balance between R&D and production. Companies require numerous engineers to create complex instruments. The high cost per employee indicates that the market values the technological sophistication and profitability of their products (especially consumables) over staffing.
%20of%20the%20company%20Singular%20Genomics%20Systems%20(OMIC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Singular-Genomics-Systems-OMIC&v=1772584120065 "Chart of market capitalization per employee (in thousands of dollars) of the company Singular Genomics Systems (OMIC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Singular Genomics Systems develops and sells next-generation genome sequencing equipment. It's a company that creates tools for scientific research. Its value lies in the technology and performance of its machines. This chart shows how the market values its innovative equipment, which can accelerate scientific discovery.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772584120124 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Singular Genomics Systems develops and sells next-generation sequencers for genome analysis. The chart shows its valuation in the Life Science sector. The high market capitalization per employee reflects the value of their technology, which is designed to make genetic analysis faster, cheaper, and more accurate for scientific and clinical laboratories.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772584120161 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Singular Genomics Systems (OMIC)
Singular Genomics Systems is a life science company that manufactures and sells DNA sequencing (genome analysis) equipment, competing with the giant Illumina. It's a "razor-thin business": selling an expensive device and then making money on consumables. This chart shows how successfully their R&D and sales teams are building their installed base.
%20Chart%20Singular%20Genomics%20Systems%20(OMIC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Singular-Genomics-Systems-OMIC&v=1772584120193 "Company Profit Per Employee (in thousands of dollars) Chart Singular Genomics Systems (OMIC)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Singular Genomics is a company that produces next-generation DNA sequencers. It's a high-tech business selling sophisticated scientific equipment and consumables. This metric reflects how successfully the company competes in the genomics technology market.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772584120263 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Singular Genomics (OMIC) is a biotech company that produces DNA sequencing equipment (a competitor to 10x Genomics and Illumina). It's a "razor blade business." This chart shows how high their R&D costs (loss per employee) are during the launch of a new device.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772584120334 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Singular Genomics Systems (OMIC)
Singular Genomics Systems develops and sells next-generation sequencers for genome analysis. This chart shows the demand for its equipment in scientific and medical laboratories. The growth in revenue per employee indicates successful sales of these sophisticated instruments and their consumables, which are key to long-term profitability.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Singular-Genomics-Systems-OMIC&v=1772584120362 "Sales chart per company employee Singular Genomics Systems (OMIC)")
Sales per employee in the market segment - Dna
Singular Genomics (OMIC) entered the market with the ambitious goal of displacing Illumina in gene sequencing. They sell their high-throughput G4 instruments for laboratories. This chart shows how much revenue each employee (engineer, salesperson) generates from sales of these complex machines and their consumables, compared to other life science manufacturers.
Sales per employee for the market as a whole
Singular Genomics (OMIC) develops and sells next-generation DNA sequencers. Its business model is a razor-sharp one: selling the devices themselves (sequencers) and high-margin consumables (kits) for them. This chart shows how successfully the company is growing its installed base of devices, which is key to future recurring revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Singular Genomics Systems (OMIC)
Singular Genomics Systems develops and sells gene sequencing equipment, attempting to compete with the industry's absolute giant, Illumina. This chart shows bearish bets. Investors are betting that Singular will be unable to dislodge Illumina from its dominant position and will lose this "David and Goliath battle."
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Singular-Genomics-Systems-OMIC&v=1772584120602 "Short Shares Chart for the Company Singular Genomics Systems (OMIC)")
Shares shorted by market segment - Dna
Singular Genomics Systems (OMIC) is challenging the DNA sequencing market leaders with new technology platforms. This is the capital-intensive "science tools" sector. This chart shows the overall investor pessimism regarding the entire segment. Growing short positions in the industry may signal expectations of price wars or that the market believes current valuations of the entire sector are overvalued.
Shares shorted by the overall market
Singular Genomics (OMIC) is an R&D project in the field of genomics. It's a "shovel" for biotech. When this chart shows rising fear, it signals a "venture winter." This means OMIC's clients (small biotechs) are freezing R&D and stopping buying its expensive, unproven equipment.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Singular Genomics Systems (OMIC)
This oscillator for Singular Genomics is an indicator of its battle with Illumina. The company released a desktop DNA sequencer (G4) in an attempt to compete with the giant. The stock was "overheated" (above 70) during the IPO hype. Slow sales, technical difficulties, and Illumina's dominance keep the stock "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Singular-Genomics-Systems-OMIC&v=1772584120694 "RSI 14 indicator chart for the company's stock Singular Genomics Systems (OMIC)")
RSI 14 Market Segment - Dna
Singular Genomics (OMIC) is the "David" challenging the "Goliath" (Illumina). They are developing their own "sequencers"—machines for reading DNA—promising to do so faster and cheaper. This chart tracks the collective sentiment in the DNA/Genomic Technologies sector. It shows when the entire industry is overhyped or oversold.
RSI 14 for the overall market
Singular Genomics (OMIC) sells R&D equipment to biotech companies. This chart tracks the pulse of its customers. In a frenzy, biotech companies (its clients) are generously funded and buying up OMIC's expensive consumables and equipment. In a panic, R&D funding dries up, and hardware budgets are the first to be cut.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OMIC (Singular Genomics Systems)
Singular Genomics (OMIC) is a DNA sequencing equipment company (G4 sequencer) seeking to challenge Illumina's dominance. This chart shows the average 12-month forecast. It reflects analysts' expectations for the rate of installation of these systems in laboratories and OMIC's ability to capture market share in the genomics market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OMIC-Singular-Genomics-Systems&v=1772584120793 "A chart showing analyst consensus forecasts for the expected stock price. OMIC (Singular Genomics Systems)")
The difference between the consensus estimate and the actual stock price OMIC (Singular Genomics Systems)
Singular Genomics (OMIC) is a contender for the DNA throne. The company has developed its own sequencer (G4), which is expected to be faster and more flexible than that of giant Illumina. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their faith in the technology and its commercial launch.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OMIC-Singular-Genomics-Systems&v=1772584120828 "A chart showing the difference between the consensus forecast and the actual stock price. OMIC (Singular Genomics Systems)")
Analyst consensus forecast for stock prices by market segment - Dna
Singular Genomics is a dark horse in the DNA sequencing race. The company is developing its own desktop sequencers, attempting to challenge the giant Illumina. This chart displays analysts' overall expectations for the *entire* DNA technology sector. It shows whether experts believe the genome-reading market will grow.
Analysts' consensus forecast for the overall market share price
Singular Genomics (OMIC) is a boutique sequencer. They produce benchtop machines (G4) that allow labs to read DNA (genomics) and RNA. They compete with the giant Illumina. This chart shows the overall risk appetite. It reflects the level of confidence analysts place in the R&D budgets of Big Pharma and the labs that are OMIC's clients.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Singular Genomics Systems
Singular Genomics is a new sequencing company. They're not Illumina; they're an R&D startup trying to break Illumina's monopoly by selling an alternative DNA reading (sequencing) machine (the G4). This chart is a summary of their battle with Goliath. It reflects their (meager) hardware sales and their (very difficult) path to commercialization.
AKIMA Market Segment Index - Dna
Singular Genomics (OMIC) is David versus Goliath (Illumina). They produce DNA sequencers—machines that read genetic code—but promise to do so faster and more flexibly. This chart compares their composite index to the sector, showing how far their sequencing technology is ahead of the competition.
The AKIM Index for the overall market
Singular Genomics is a developer of next-generation DNA sequencing systems (G4), offering speed and flexibility. It competes with Illumina. This chart, reflecting the market average, is just a backdrop. It helps assess how this player in the scientific tools market stacks up against overall macroeconomic trends and laboratory budgets.
